Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Wellness Focus Cayman Islands.
Press releases published on May 6, 2025
Alector to Participate in Upcoming Healthcare Conferences
GlobeNewswire
·
May 6, 2025
SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that …
Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update
GlobeNewswire
·
May 6, 2025
Dose optimization and RP2D determination on schedule for completion in Q4 2025 for the Nectin-4 ADC CRB-701 in HNSCC, cervical and mUC tumors SAD/MAD study on schedule for completion in Q3 2025 for the anti-obesity CB1 inverse agonist CRB-913 Dose …
Quoin Pharmaceuticals to Announce First Quarter 2025 Financial Results on Tuesday, May 13, 2025
GlobeNewswire
·
May 6, 2025
ASHBURN, Va., May 06, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to release its …
Cogent Biosciences Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 6, 2025
Three Registration-Directed Top-line Data Readouts Remain on Track in 2025: SUMMIT in NonAdvanced SM expected in July, APEX in Advanced SM expected in second half of the-year and PEAK in GIST expected by end of year Ended 1Q 2025 with $245.7 million in …
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results
GlobeNewswire
·
May 6, 2025
SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, …
Catheter Precision, Inc. Completes Acquisition of Cardionomic Heart Failure Assets
GlobeNewswire
·
May 6, 2025
FORT MILL, S.C., May 06, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that its 82% …
BioCardia Initiates Patient Enrollment at University of Wisconsin at Madison for Ongoing CardiAMP HF II Pivotal Study
GlobeNewswire
·
May 6, 2025
CardiAMP HF II is Evaluating the CardiAMP™ Cell Therapy Product for Treating Patients with Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF) and Elevated Markers of Cardiac Stress Dr. Amish Raval, Professor of Medicine at the University of …
Galimedix Therapeutics completes single ascending dose part of Phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modulator
GlobeNewswire
·
May 6, 2025
GAL-101 well tolerated; excellent safety and pharmacokinetic profile strongly supports oral administration Next arms of study, including multiple ascending dose (MAD), underway and expected to complete in late 2025 Planned indications include dry age- …
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
GlobeNewswire
·
May 6, 2025
BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David …
Pacira BioSciences to Present 3-Year Safety and Efficacy Data of PCRX-201 Following Single Intra-Articular Injection for Moderate-to-Severe Knee Osteoarthritis
GlobeNewswire
·
May 6, 2025
-- Data will be featured at EULAR Annual Congress – BRISBANE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of …
Three New Medical Centers Adopt Daxor's Blood Volume Diagnostic Signaling Growing Clinical Acceptance
GlobeNewswire
·
May 6, 2025
Daxor’s Innovative ezBVA Lab Service Drives Accessibility and Operational Efficiency Oak Ridge, TN, May 06, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces significant …
MIMEDX to Present at the BofA Securities 2025 Healthcare Conference
GlobeNewswire
·
May 6, 2025
MARIETTA, Ga., May 06, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the BofA Securities 2025 Healthcare Conference in Las Vegas, NV. …
Compass Therapeutics to Participate in Upcoming May Investor Events
GlobeNewswire
·
May 6, 2025
BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate in the …
Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
GlobeNewswire
·
May 6, 2025
THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its first quarter 2025 financial results on Tuesday, May 13, 2025, after the markets close. Management will conduct …
Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate
GlobeNewswire
·
May 6, 2025
RESEARCH TRIANGLE PARK, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other ophthalmic …
Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer
GlobeNewswire
·
May 6, 2025
Topline data shows statistically significant improvement in overall survival in elraglusib plus GnP combination arm versus GnP control arm Elraglusib/GnP combination arm demonstrated substantial improvement in median overall survival since the last data …
Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 6, 2025
On track to announce the primary endpoint results from the atacicept pivotal Phase 3 ORIGIN trial in IgA Nephropathy (IgAN) in 2Q 2025; planning for Biologics License Application (BLA) submission for atacicept accelerated approval to the U.S. FDA in 4Q …
Krystal Biotech Announces First Quarter 2025 Financial and Operating Results
GlobeNewswire
·
May 6, 2025
VYJUVEK approved in Europe for the treatment of DEB patients from birth $88.2 million in 1Q VYJUVEK revenue and $429.4 million since launch in Q3 2023 Second ophthalmic program in clinic - KB801 for the treatment of neurotrophic keratitis Upcoming clinical …
VAXIL: SHARE CONSOLIDATION
GlobeNewswire
·
May 6, 2025
Not for distribution by US newswire or in United States TORONTO, May 06, 2025 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), is pleased to make the following updates regarding the Company’s activities. Vaxil announces …
OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
GlobeNewswire
·
May 6, 2025
-- Continued progress in the PIKture-01 trial; on track to report additional data in the second half of 2025, including mature single agent and initial combination data -- Expansion of the Company’s PI3Ka franchise with the planned announcement of a pan- …